Literature DB >> 2104084

Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome.

L J O'Donnell1, A J Watson, D Cameron, M J Farthing.   

Abstract

The effect of a single subcutaneous injection of octreotide (50 micrograms) on mouth-to-caecum transit time was determined in patients with the irritable bowel syndrome who complained of bowel frequency, and in healthy volunteers. The assessment of mouth-to-caecum transit time was performed by monitoring breath hydrogen concentration and noting a sustained 10 p.p.m. rise after ingestion of lactulose 40 ml. Measurements were performed fasting, and on a separate day, after a standard breakfast which included 40 ml lactulose. The studies were performed double-blind in a pre-determined random order. Octreotide prolonged mouth-to-caecum transit time in irritable bowel syndrome patients and healthy subjects by factors of 2.4 and 2.6 after lactulose when fasting, respectively, and by factors of 2.8 and 2.6 after the breakfast which contained lactulose. The upper gastrointestinal transit rate was similar in irritable bowel syndrome patients and healthy controls.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104084     DOI: 10.1111/j.1365-2036.1990.tb00463.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Chronic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

2.  Small Bowel Dysmotility.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1998-12

Review 3.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

4.  Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones.

Authors:  M J Veysey; L A Thomas; A I Mallet; P J Jenkins; G M Besser; J A Wass; G M Murphy; R H Dowling
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 5.  Irritable bowel syndrome: recent and novel therapeutic approaches.

Authors:  Viola Andresen; Michael Camilleri
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.

Authors:  M Bradette; M Delvaux; G Staumont; J Fioramonti; L Bueno; J Frexinos
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 7.  Octreotide in the treatment of refractory diarrhoea and intestinal fistulae.

Authors:  M J Farthing
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 8.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

9.  Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.

Authors:  A Foxx-Orenstein; M Camilleri; D Stephens; D Burton
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

10.  Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders.

Authors:  K Haruma; J A Wiste; M Camilleri
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.